新型PD-1抑制剂prolgolimab拓展晚期黑色素瘤治疗选择
MIRACULUM研究评估两种prolgolimab给药方案治疗晚期黑色素瘤,1年随访客观缓解率分别为38.1%和28.6%,均超过预设28%阈值;2年随访无进展生存率33.3%和30.2%,总生存率57.1%和46.0%,安全性可控。
要点
- 两种给药方案客观缓解率均超过28%预设阈值。
- 2年无进展生存率分别为33.3%和30.2%。
- 3-4级治疗相关不良事件发生率分别为12.7%和3.2%。
核心结论
- MIRACULUM研究两个治疗组均达到主要终点,prolgolimab在晚期黑色素瘤中显示显著抗肿瘤活性和可控安全性。
研究设计与样本
- 多中心开放标签平行组II期试验,纳入126例晚期皮肤或非皮肤黑色素瘤患者,按1:1随机分配至1 mg/kg每2周组或3 mg/kg每3周组。
- 随机分层因素包括ECOG评分0或1、乳酸脱氢酶水平升高或正常、既往是否接受过全身治疗。
- 主要终点为独立中心评审按免疫相关RECIST评估的客观缓解率。
主要发现
- 1年数据截止时,中位随访时间分别为13.8个月和14.5个月,客观缓解率分别为38.1%和28.6%。
- 3-4级治疗相关不良事件发生率分别为12.7%和3.2%。
- 2年探索性分析中位随访时间分别为25.4个月和25.7个月,2年无进展生存率分别为33.3%和30.2%,2年总生存率分别为57.1%和46.0%。
关键数值与推荐
- 主要终点假设每个给药方案总体缓解率超过28%,并在每个治疗组中独立检验。
- 客观缓解按免疫相关RECIST由独立中心评审评估。
临床怎么用
- prolgolimab两种给药方案均可作为晚期黑色素瘤的治疗选择,需关注3-4级治疗相关不良事件。
局限性
- 2年随访疗效分析为探索性,未在方案中预先指定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prolgolimab is an IgG1 anti-PD-1 (programmed cell death protein 1) monoclonal antibody containing the Fc-silencing 'LALA' mutation. We assessed the efficacy and safety of two dosing regimens of prolgolimab in patients with advanced melanoma in a multicenter open-label parallel-arm phase II trial (MIRACULUM). We present the final analysis after 1 year of follow-up and additional efficacy results from 2 years of follow-up. METHODS: Patients with advanced cutaneous or non-cutaneous melanoma, including stable brain metastasis, without autoimmune disease and who underwent no prior targeted therapy, anti-PD-(L)1 or anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) therapy were randomly assigned (1:1) to receive prolgolimab in 2 dosing regimens, 1 mg/kg every 2 weeks (arm 1) or 3 mg/kg every 3 weeks (arm 2), until disease progression or intolerable toxicity. Randomisation was stratified based on performance status (Eastern Cooperative Oncology Group 0 or 1), lactate dehydrogenase levels (elevated or normal) and prior systemic therapy (naive or previously treated). The primary outcome was the objective response rate, assessed as per immune-related Response Evaluation Criteria in Solid Tumours by independent central review. The hypothesis that each dosing regimen of prolgolimab has an overall response rate >28% was tested independently for each study arm comprising all patients who received at least one dose of prolgolimab. Exploratory assessment of efficacy, including subgroup analysis, at 2 years of follow-up was not specified in the protocol. This study is registered withClinicalTrials.gov(NCT03269565). RESULTS: Between August 2017 and March 2018, 126 patients with advanced melanoma were enrolled. At main 1-year data cut-off, the median follow-up was 13.8 and 14.5 months in arm 1 and 2, respectively. An objective response was observed in 38.1% of patients (arm 1) and in 28.6% (arm 2). Grade III-IV treatment-related adverse events occurred in 12.7% and 3.2% of patients in arm 1 and 2, respectively. For exploratory efficacy analysis, the median follow-up was 25.4 and 25.7 months in arm 1 and 2, respectively. The 2-year progression-free survival was 33.3% in arm 1 and 30.2% in arm 2, and the 2-year overall survival was 57.1% and 46.0%, respectively. CONCLUSIONS: The MIRACULUM study met its primary end-point in both the study arms. Prolgolimab showed significant antitumour activity and a manageable safety profile in patients with advanced melanoma.
引用
- Tjulandin S, Demidov L, Moiseyenko V, et al. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice. Eur J Cancer. 2021. PMID: 33872982. doi:10.1016/j.ejca.2021.02.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。